Pharmaceutical firm Sinclair IS Pharma saw a big jump in revenues in the last year driven by international sales.
In a trading statement the firm said it expected revenue for the year to the end of June to have grown by 56% to reach £51.3m
Likeforlike revenue growth was expected to be 11.3% for the year, it said.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Chief Executive Chris Spooner put the strong performance down to a combination of strong growth from international operations, in particular Asia, and more modest like-for-like growth in Europe.
"We have continued to improve the growth prospects of our product portfolio by acquisition, and brand extension," he said.
"This combined with multiple product launches in Asia, mean that we are well positioned to deliver further growth in the coming year."
International operations saw like-for-like growth of 36% for the full year, including growth in Asia of 155% as a result of multiple product launches.
The firm said it expected international growth to continue in2013 with several new launches in Asia.
-
Cash in on the growth prospects of Europe's companiesOpinion Marcel Stötzel, co-portfolio manager of the Fidelity European Trust, selects three stocks
-
Is the AI boom another dotcom bubble?25 years on from the dotcom bubble bursting, is it time for investors to consider the sustainability of the AI boom in the stock market?
